Product Datasheet  
Isocitrate dehydrogenase/IDH1 Antibody  
Catalog Number: 48489  
Technical:tech@swbio.com  
Information:info@swbio.com  
Description  
  • host_species：  
  • Mouse
  • Amount：  
  • 100μgμg
  • Swiss-Prot No.：  
  • Swiss-Prot#:O75874
  • Form of Antibody：  
  • 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.
  • Storage：  
  • Store at -20˚C
  • Immunogen：  
  • recombinant protein
  • reactivity：  
  • Hu, zebrafish
  • appl_detail：  
  • WB: 1:1,000
    IHC: 1:100-1:200


  • other_names：  
  • Cytosolic NADP isocitrate dehydrogenase antibody
    Cytosolic NADP-isocitrate dehydrogenase antibody
    Epididymis luminal protein 216 antibody
    Epididymis secretory protein Li 26 antibody
    HEL-216 antibody
    HEL-S-26 antibody
    ICDH antibody
    IDCD antibody
    IDH antibody
    IDH1 antibody
    IDHC_HUMAN antibody
    IDP antibody
    IDPC antibody
    Isocitrate dehydrogenase [NADP] cytoplasmic antibody
    Isocitrate dehydrogenase 1 (NADP+) soluble antibody
    NADP dependent isocitrate dehydrogenase cytosolic antibody
    NADP dependent isocitrate dehydrogenase peroxisomal antibody
    NADP(+)-specific ICDH antibody
    Oxalosuccinate decarboxylase antibody
    PICD antibody
  • Purification：  
  • ProA affinity purified
  • Specificity：  
  • Applications：  
  • WB, IHC
  • Background：  
  • Isocitrate dehydrogenase (IDH) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2. In humans, IDH exists in three isoforms: IDH3 catalyzes the third step of the citric acid cycle while converting NAD+ to NADH in the mitochondria. The isoforms IDH1 and IDH2 catalyze the same reaction outside the context of the citric acid cycle and use NADP+ as a cofactor instead of NAD+. They localize to the cytosol as well as the mitochondrion and peroxisome. Mutations in IDH1 are also implicated in cancer. Originally mutations in IDH1 were detected in an integrated genomic analysis of human glioblastoma multiforme. In addition to being mutated in diffuse gliomas, IDH1 has also been shown to harbor mutations in human acute myeloid leukemia (AML).



 
© Signalway Biotechnology All Rights Reserved.